11:43 AM EDT, 07/24/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Wednesday that its twice-yearly lenacapavir injections were "highly effective" in preventing human immunodeficiency virus, or HIV, in cisgender women during a phase 3 trial.

The new data provide details on the efficacy, safety and tolerability of lenacapavir injections. In June, interim analysis showed that lenacapavir demonstrated zero infections, full efficacy and superiority to background HIV incidence for the investigational use of HIV prevention in cisgender women.

There were no new safety concerns identified, and lenacapavir was generally well tolerated, the company said. The data were presented at the International AIDS Conference in Munich, Germany and were published in The New England Journal of Medicine.

Shares of Gilead Sciences ( GILD ) rose more than 1% in recent trading.

Price: 72.45, Change: +1.28, Percent Change: +1.80